How Rybelsus and Compounded Semaglutide work — mechanism comparison
Rybelsus (semaglutide) and Compounded Semaglutide (semaglutide (compounded)) belong to overlapping but distinct drug classes. Both work via the incretin (gut-hormone) pathway, but they have different molecular targets:
- Rybelsus (semaglutide) — GLP-1 receptor agonist
- Compounded Semaglutide (semaglutide (compounded)) — GLP-1 receptor agonist
This mechanistic difference matters because it determines: efficacy (how much weight loss / blood-sugar control you can expect), side-effect profile, dosing schedule, and which patients may benefit most. Read more in our Rybelsus mechanism guide and Compounded Semaglutide mechanism guide.
Efficacy head-to-head
In their respective pivotal trials, mean body-weight reduction reached:
- Rybelsus: 14.9% at 68 weeks (trial: STEP-1)
- Compounded Semaglutide: 14.9% at 68 weeks (trial: STEP-1)
The two are effectively equivalentin trial-mean efficacy (<1% difference). Individual response variability is far larger than this between-drug difference.
Side-by-side radar: Rybelsus vs Compounded Semaglutide
Editorial scoring across 5 dimensions, overlaid. Higher area = better overall fit.
| Axis | Rybelsus | Compounded Semaglutide |
|---|---|---|
| Efficacy | 8 | 8 |
| Convenience | 9 | 9 |
| Affordability | 6 | 6 |
| Tolerance | 5 | 5 |
| Evidence | 10 | 10 |
Higher score = better on that axis. Editorial scoring; not a substitute for prescriber judgment.
Side effects compared
Both drugs share the GLP-1 class side-effect profile — primarily gastrointestinal (nausea, diarrhea, constipation, vomiting) in early treatment, fading as the body adapts. Both carry the FDA boxed warning for thyroid C-cell tumors and contraindications for personal/family history of medullary thyroid carcinoma.
Comparative trial data on common side effects (rates may differ from real-world):
- Nausea rate (Rybelsus): 44%
- Nausea rate (Compounded Semaglutide): 44%
- Diarrhea rate (Rybelsus): 30%
- Diarrhea rate (Compounded Semaglutide): 30%
Patients who tolerate one GLP-1 well often (but not always) tolerate another. Switching between class members typically requires re-titration regardless of prior tolerability. See full side-effect breakdowns for Rybelsus and Compounded Semaglutide.
Dosing schedule comparison
Both medications use step-up titration to minimize side effects, but the schedule details differ:
Rybelsus
- Week 1–4: 0.25 mg
- Week 5–8: 0.5 mg
- Week 9–12: 1.0 mg
- Week 13+: 1.7–2.4 mg
Compounded Semaglutide
- Week 1–4: 0.25 mg
- Week 5–8: 0.5 mg
- Week 9–12: 1.0 mg
- Week 13+: 1.7–2.4 mg
See full titration guides for Rybelsus dosing and Compounded Semaglutide dosing.
Cost comparison
Cost differences between Rybelsus and Compounded Semaglutide depend on insurance coverage, manufacturer savings programs, and partner-network pricing — not just retail price.
- Average retail price (Rybelsus): $968/month
- Average retail price (Compounded Semaglutide): $250/month
- Rybelsus savings card: as low as $10/month for eligible commercial-insured
- Compounded Semaglutide savings card: as low as $0/month for eligible commercial-insured
For most patients, the actual out-of-pocket cost is driven by: (1) what your insurance formulary tier places Rybelsus vs Compounded Semaglutide, (2) whether you qualify for manufacturer savings cards (commercial insurance only), and (3) telehealth partner network availability. Full cost breakdowns: Rybelsus cost guide · Compounded Semaglutide cost guide.
Which one to choose — decision factors
There's no single «better» drug — the right choice depends on individual circumstances. The key decision factors:
Choose Rybelsus if…
- Your insurance covers it but not Compounded Semaglutide
- Your prescriber has more experience with it
Choose Compounded Semaglutide if…
- Your insurance covers it but not Rybelsus
- Your prescriber has more experience with it
Switching from Rybelsus to Compounded Semaglutide (or vice versa)
Switching between Rybelsus and Compounded Semaglutide (different active ingredients) typically requires restarting titration from the lowest doseof the new drug. Different molecules have different potencies — your tolerated dose of one doesn't map directly to the other. Plan for:
- Return of titration-period side effects (nausea, GI) for 2-4 weeks on restart
- Possibly temporary weight regain during the transition
- Fresh insurance prior-authorization (different drug = new PA)
- 2-4 weeks for the new drug to reach steady-state plasma levels
FAQ — Rybelsus vs Compounded Semaglutide
Are Rybelsus and Compounded Semaglutide the same drug?
No — they contain different active ingredients (semaglutide and semaglutide (compounded)). They belong to similar drug classes (GLP-1 family) but work via slightly different molecular targets.
Which is more effective for weight loss?
In separate pivotal trials, Compounded Semaglutide produced 0.0 percentage points more weight loss than Rybelsus on average. However, these were separate trials with different populations — not head-to-head comparison. Individual response variability is also large. Most patients achieve clinically meaningful weight loss with either drug.
Can I take Rybelsus and Compounded Semaglutide together?
No. Combining two GLP-1 receptor agonists provides no added benefit and dramatically increases side-effect risk. Standard practice is to switch between them, not combine.
Which has fewer side effects?
Side-effect profiles are broadly similar across GLP-1 medications — primarily GI effects that fade with adaptation. Individual tolerance varies. Trial data shows comparable rates of nausea, diarrhea, and other common effects between Rybelsus and Compounded Semaglutide.
Will my insurance cover one but not the other?
Often yes. Insurance formularies are negotiated separately per drug — Rybelsus may be on Tier 2 of your plan while Compounded Semaglutide is Tier 4 (or excluded). Check your formulary before assuming both are equally accessible.
Editorial comparison based on FDA prescribing information and published clinical data. Not a substitute for prescriber consultation. Full medical disclaimer.